Walleye Trading LLC Takes $45,000 Position in Chimerix, Inc. (NASDAQ:CMRX)

Walleye Trading LLC purchased a new stake in shares of Chimerix, Inc. (NASDAQ:CMRXGet Rating) in the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 21,397 shares of the biopharmaceutical company’s stock, valued at approximately $45,000.

Several other institutional investors have also made changes to their positions in the company. State Street Corp lifted its holdings in shares of Chimerix by 14.2% during the 1st quarter. State Street Corp now owns 4,561,868 shares of the biopharmaceutical company’s stock valued at $20,893,000 after buying an additional 568,498 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Chimerix by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 3,832,252 shares of the biopharmaceutical company’s stock worth $17,552,000 after purchasing an additional 105,441 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Chimerix by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,951,521 shares of the biopharmaceutical company’s stock worth $8,938,000 after purchasing an additional 206,990 shares during the last quarter. Monaco Asset Management SAM acquired a new stake in Chimerix in the 2nd quarter worth approximately $3,077,000. Finally, Goldman Sachs Group Inc. lifted its holdings in Chimerix by 45.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 749,092 shares of the biopharmaceutical company’s stock worth $3,431,000 after purchasing an additional 232,839 shares during the last quarter. 63.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CMRX shares. StockNews.com upgraded Chimerix from a “hold” rating to a “buy” rating in a report on Friday, November 4th. Capital One Financial started coverage on Chimerix in a report on Wednesday, September 7th. They issued an “overweight” rating and a $7.00 target price for the company. Four equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $9.60.

Chimerix Stock Down 0.5 %

Shares of CMRX stock opened at $2.21 on Monday. Chimerix, Inc. has a 12 month low of $1.27 and a 12 month high of $7.42. The firm has a market cap of $194.58 million, a PE ratio of 1.26 and a beta of 1.08. The stock has a 50 day moving average of $1.93 and a 200-day moving average of $2.15.

Insider Transactions at Chimerix

In other Chimerix news, Director Fred A. Middleton purchased 20,000 shares of the business’s stock in a transaction dated Thursday, September 29th. The stock was bought at an average cost of $1.86 per share, for a total transaction of $37,200.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at $74,400. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 8.20% of the company’s stock.

Chimerix Company Profile

(Get Rating)

Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.

Featured Stories

Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRXGet Rating).

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.